Impact of an Early Prostate-Specific Antigen Response on Biochemical Progression During Upfront Androgen Receptor Signal Inhibitor Therapy for Metastatic Hormone-Sensitive Prostate Cancer.

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY

Urologia Internationalis Pub Date : 2025-05-22 DOI:10.1159/000546327

Asumi Nirazuka, Akinori Nakayama, Minoru Inoue, Hiroki Tsujioka, Keita Izumi, Kiyoshi Setoguchi, Gaku Arai, Kazutaka Saito

{"title":"Impact of an Early Prostate-Specific Antigen Response on Biochemical Progression During Upfront Androgen Receptor Signal Inhibitor Therapy for Metastatic Hormone-Sensitive Prostate Cancer.","authors":"Asumi Nirazuka, Akinori Nakayama, Minoru Inoue, Hiroki Tsujioka, Keita Izumi, Kiyoshi Setoguchi, Gaku Arai, Kazutaka Saito","doi":"10.1159/000546327","DOIUrl":null,"url":null,"abstract":"Introduction: We examined the impact of prostate-specific antigen (PSA) response, which is associated with survival, on patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen receptor signal inhibitors (ARSIs).Methods: We retrospectively reviewed 82 patients with mHSPC who received upfront ARSI treatment. The primary endpoint was PSA progression-free survival (PFS). Patients whose PSA levels decreased to ≤0.2 ng/mL at 3 months after ARSI initiation were classified as deep early, those with >0.2-≤1.0 ng/mL as early, and others as non- PSA responders.Results: The median age of patients was 73 years old, and the median baseline PSA value was 361 ng/ml. Among 82 patients, 32 (39%), 16 (20%) and 34 (41%) were categorized into deep early, early and non-early PSA responders, respectively. There was a significant association between PSA response status, hemoglobin and PSA value. During follow-up (median, 23.0 months), 31 (37.8%) patients experienced PSA progression. The PSA progression rates of the deep early, early, and non-early PSA responders were 15.6%, 31.2%, and 61.8% (p < 0.001), and their 2-year PSA PFS rates were 90.5%, 70.7%, and 38.9%, respectively.Conclusion: An early PSA response within 3 months after ARSI initiation was associated with PSA progression in patients with mHSPC.","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-18"},"PeriodicalIF":1.5000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Internationalis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546327","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: We examined the impact of prostate-specific antigen (PSA) response, which is associated with survival, on patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen receptor signal inhibitors (ARSIs).

Methods: We retrospectively reviewed 82 patients with mHSPC who received upfront ARSI treatment. The primary endpoint was PSA progression-free survival (PFS). Patients whose PSA levels decreased to ≤0.2 ng/mL at 3 months after ARSI initiation were classified as deep early, those with >0.2-≤1.0 ng/mL as early, and others as non- PSA responders.

Results: The median age of patients was 73 years old, and the median baseline PSA value was 361 ng/ml. Among 82 patients, 32 (39%), 16 (20%) and 34 (41%) were categorized into deep early, early and non-early PSA responders, respectively. There was a significant association between PSA response status, hemoglobin and PSA value. During follow-up (median, 23.0 months), 31 (37.8%) patients experienced PSA progression. The PSA progression rates of the deep early, early, and non-early PSA responders were 15.6%, 31.2%, and 61.8% (p < 0.001), and their 2-year PSA PFS rates were 90.5%, 70.7%, and 38.9%, respectively.

Conclusion: An early PSA response within 3 months after ARSI initiation was associated with PSA progression in patients with mHSPC.

查看原文本刊更多论文

早期前列腺特异性抗原反应对转移性激素敏感前列腺癌前期雄激素受体信号抑制剂治疗期间生化进展的影响。

前言：我们研究了前列腺特异性抗原（PSA）反应对接受雄激素受体信号抑制剂（ARSIs）治疗的转移性激素敏感性前列腺癌（mHSPC）患者的影响，PSA反应与生存率相关。方法：我们回顾性分析了82例接受前期ARSI治疗的mHSPC患者。主要终点是PSA无进展生存期（PFS）。在ARSI开始后3个月PSA水平降至≤0.2 ng/mL的患者被归类为深早患者，>0.2-≤1.0 ng/mL的患者被归类为早患者，其他患者被归类为无PSA应答者。结果：患者的中位年龄为73岁，中位基线PSA值为361 ng/ml。在82例患者中，32例（39%）、16例（20%）和34例（41%）分别被划分为深早期、早期和非早期PSA应答者。PSA反应状态、血红蛋白与PSA值之间存在显著相关性。在随访期间（中位23.0个月），31例（37.8%）患者出现PSA进展。深早期、早期和非早期PSA应答者的PSA进展率分别为15.6%、31.2%和61.8% (p < 0.001)，其2年PSA PFS率分别为90.5%、70.7%和38.9%。结论：ARSI开始后3个月内的早期PSA反应与mHSPC患者的PSA进展相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urologia Internationalis 医学-泌尿学与肾脏学

CiteScore

3.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： Concise but fully substantiated international reports of clinically oriented research into science and current management of urogenital disorders form the nucleus of original as well as basic research papers. These are supplemented by up-to-date reviews by international experts on the state-of-the-art of key topics of clinical urological practice. Essential topics receiving regular coverage include the introduction of new techniques and instrumentation as well as the evaluation of new functional tests and diagnostic methods. Special attention is given to advances in surgical techniques and clinical oncology. The regular publication of selected case reports represents the great variation in urological disease and illustrates treatment solutions in singular cases.